Table 2 Determinants of time to achieve Pt Pain ≤ 15 mm and achievement at week 100 among guselkumab-randomized patients (N = 493)

Age, years

1.00 (0.99–1.01)

-

1.00 (0.98–1.02)

-

Sex (male vs. female)

1.07 (0.84–1.36)

-

1.09 (0.74–1.61)

-

Race (White vs. Asian)

1.71 (0.52–5.59)

-

1.74 (0.44–6.86)

-

BMI, kg/m²

0.98 (0.96–1.00)

0.98 (0.96–1.00)^*

0.97 (0.94–1.00)^*

0.97 (0.94–1.00)^*

Guselkumab treatment (Q4W vs. Q8W)

0.92 (0.73–1.17)

-

0.90 (0.62–1.32)

-

HAQ-DI score (0–3)

-

-

-

-

PtGA VAS (0–10 cm)

-

-

-

-

Pt Pain VAS (0–10 cm)

0.99 (0.98–1.00)^†

0.99 (0.98–1.00)^†

0.98 (0.97–1.00)^†

0.98 (0.97–1.00)^†

FACIT-Fatigue^§

1.02 (1.00–1.03)^*

1.02 (1.00–1.03)^*

1.02 (1.00–1.05)

1.02 (1.00–1.05)^*

History of depression (N = 8)

0.86 (0.32–2.32)

-

0.95 (0.22–4.08)

-

Suicidal ideation or non-suicidal self-injurious behaviour (N = 9)

0.78 (0.24–2.55)

-

0.49 (0.11–2.12)

-

History of fibromyalgia (N = 3)

0.71 (0.56–0.91)^†

0.70 (0.55–0.90)^†

0.59 (0.40–0.87)^†

0.58 (0.40–0.86)^†